Zaid S Al-Kadhimi, MD

Associate Professor

  • 665 Citations
  • 16 h-Index
20042020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Zaid S Al-Kadhimi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 665 Citations
  • 16 h-Index
  • 32 Article
  • 8 Review article
  • 3 Letter

Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia

Dhakal, P., Lyden, E., Lee, A., Michalski, J., Al-Kadhimi, Z. S., Maness, L. J., Gundabolu, K. & Bhatt, V. R., Mar 2020, In : Clinical Lymphoma, Myeloma and Leukemia. 20, 3, p. e131-e136

Research output: Contribution to journalArticle

  • Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

    Holstein, S. A., Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L. & McCarthy, P. L., Jan 2020, In : Biology of Blood and Marrow Transplantation. 26, 1, p. e7-e15

    Research output: Contribution to journalReview article

  • Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients

    Michalski, J. M., Lyden, E. R., Lee, A. J., Al-Kadhimi, Z. S., Maness, L. J., Gundabolu, K. & Bhatt, V. R., Jun 2019, In : Future Oncology. 15, 17, p. 1989-1995 7 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    Bolaños-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Chen, Y. B., Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J. & 14 others, Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C. & Koreth, J., Mar 2019, In : The Lancet Haematology. 6, 3, p. e132-e143

    Research output: Contribution to journalArticle

  • 18 Scopus citations

    A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

    Modi, D., Al-Kadhimi, Z., Chen, W., Jang, H., Deol, A., Ayash, L., Bhutani, D., Alavi, A., Ratanatharathorn, V. & Uberti, J. P., Apr 2018, In : American Journal of Hematology. 93, 4, p. E96-E98

    Research output: Contribution to journalLetter